Search results for "ADO"

showing 10 items of 13500 documents

Possible association between obesity and periodontitis in patients with Down syndrome

2017

Background The present study was carried out to evaluate the possible association between obesity and periodontitis in patients with DS, and to explore which measure of obesity is most closely correlated to periodontitis. Material and Methods A prospective observational study was made to determine whether obesity is related to periodontal disease in patients with DS. The anthropometric variables were body height and weight, which were used to calculate BMI and stratify the patients into three categories: < 25(normal weight), 25-29.9 (overweight) and ≥ 30.0 kg/m2 (obese). Waist circumference and hip circumference in turn was recorded as the greatest circumference at the level of the buttocks…

0301 basic medicineAdultMalemedicine.medical_specialtyobesityWaistAdolescentDown syndromeperiodontal diseaseContext (language use)Overweight03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineBayesian multivariate linear regressionmedicineHumansObesityProspective StudiesProspective cohort studyPeriodontitisGeneral DentistryPeriodontitis030109 nutrition & dieteticsbusiness.industryResearchnutritional and metabolic diseases030206 dentistryAnthropometryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistryObesityOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemalemedicine.symptomDown Syndromebusiness
researchProduct

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

2020

Monosomy 7 [-7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with -7/del(7q) as isolated cytogenetic abnormality (86 with del(7q) and 194 with -7). Patients with del(7q) or -7 had similar demographic and disease-related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in -7 and 73% in del(7q) group). Median number of mutations per patient was 2 (range 0-8). There was no difference in mutation frequen…

0301 basic medicineAdultMalemyelodysplastic syndromes chromosome abnormalities prognosisCancer Researchmedicine.medical_specialtyAdolescentSomatic cellTp53 mutationGastroenterology03 medical and health sciences0302 clinical medicinePartial lossCytogenetic AbnormalityInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMutation frequencyAgedChromosome 7 (human)Aged 80 and overbusiness.industryMyelodysplastic syndromesHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisMutational analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesMutationFemaleChromosome DeletionbusinessChromosomes Human Pair 7
researchProduct

Molecular and clinical studies in five index cases with novel mutations in the GLA gene

2016

Fabry disease is a metabolic and lysosomal storage disorder caused by the functional defect of the α-galactosidase A enzyme; this defect is due to mutations in the GLA gene, that is composed of seven exons and is located on the long arm of the X-chromosome (Xq21–22). The enzymatic deficit is responsible for the accumulation of glycosphingolipids in lysosomes of different cellular types, mainly in those ones of vascular endothelium. It consequently causes a cellular and microvascular dysfunction. In this paper, we described five novel mutations in the GLA gene, related to absent enzymatic activity and typical manifestations of Fabry disease. We identified three mutations (c.846_847delTC, p.E…

0301 basic medicineAdultMalep.R227Pnovel moutationAdolescentc.639 + 5G > TMutation MissenseBiologyLeft ventricular hypertrophy03 medical and health sciencesExonYoung Adult0302 clinical medicineSettore BIO/13 - Biologia ApplicataGeneticsmedicinefabry; novel moutationMissense mutationAlpha-galactosidase AHumansPoint MutationCornea verticillataGenetic Predisposition to DiseaseChildfabryGLA genec.846_847delTCGeneticsAlpha-galactosidasePoint mutationFabry disease; Alpha-galactosidase A; c.846_847delTC; p.E341X; p.C382X; p.R227P; c.639 + 5G > Tp.E341XGeneral MedicineMiddle Agedmedicine.diseaseMolecular biologyFabry diseaseStop codon030104 developmental biologyp.C382Xalpha-Galactosidasebiology.proteinFabry DiseaseFemalemedicine.symptom030217 neurology & neurosurgery
researchProduct

Kinetics of the early development of uniparental human haploid embryos

2016

Objective: To describe morphokinetically the early development of human haploid parthenotes and androgenotes and to compare them with euploid embryos. Design: Experimental study of kinetics. Setting: University-affiliated private fertility center. Patient(s): Experimental haploid parthenotes and androgenotes. Intervention(s): Kinetic study of early development (up to eight cells) of 8 parthenotes, 10 androgenotes, and 20 euploid embryos. Main Outcome Measure(s): Timing of the first seven cleavages determined according to embryo origin, then calculation of the duration of the second and third cell cycles (cc2 and cc3) of whole embryos and individual cells. Result(s): Parthenotes and androgen…

0301 basic medicineAdultanimal structuresAdolescentmedicine.medical_treatmentEmbryonic DevelopmentBiologyHaploidyIntracytoplasmic sperm injectionAndrology03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansSperm Injections IntracytoplasmichumanGenetics030219 obstetrics & reproductive medicineOutcome measuresObstetrics and GynecologyEmbryoOocyte activationAndrogenoteAneuploidyKineticshaploid030104 developmental biologyReproductive Medicinemorphokineticparthenoteembryonic structuresPloidy
researchProduct

Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.

2021

Objective To compare ovarian response and reproductive outcomes in oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) versus those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. Design A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes. The reproductive outcomes of the recipients were retrospectively analyzed later. Setting A university-affiliated private in vitro fertilization center. Patient(s) We randomly divided 318 donors into 2 groups in a 1:1 ratio. The oocytes obtained were assigned to 364 recipi…

0301 basic medicineAdultmedicine.drug_classmedia_common.quotation_subjectMedroxyprogesterone AcetateGonadotropin-releasing hormone antagonistAndrologyGonadotropin-Releasing Hormone03 medical and health sciences0302 clinical medicineOvulation InductionPregnancyFollicular phasemedicineMedroxyprogesterone acetateHumansProspective StudiesGanirelixOvulationmedia_common030219 obstetrics & reproductive medicineEstradiolOocyte Donationbusiness.industryAntagonistObstetrics and GynecologyLuteinizing HormoneMiddle AgedFollicular fluid030104 developmental biologyReproductive MedicineFemaleLuteinizing hormonebusinessmedicine.drugFertility and sterility
researchProduct

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer

2019

Research question: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? Design: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. Results: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tu…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentDisease-free survivalStimulationBreast NeoplasmsKaplan-Meier EstimateOverall survival rateGastroenterologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerBreast cancerOvulation InductionInternal medicinemedicineHumansFertility preservationProspective StudiesStage (cooking)Neoplasm MetastasisFertility preservationRetrospective StudiesCryopreservation030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyFertility PreservationHistologymedicine.diseaseVitrificationConfidence intervalSurvival Rate030104 developmental biologyTreatment OutcomeReproductive MedicineOocytesFemaleOvarian stimulationNeoplasm Recurrence LocalbusinessDevelopmental BiologyCohort studyHormoneFollow-Up Studies
researchProduct

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

2018

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%). …

0301 basic medicineAdultmedicine.medical_specialtyAntimetabolites AntineoplasticMyeloidAdolescentDatabases FactualAzacitidineDecitabineSalvage therapyDecitabineCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRefractoryInternal medicinehemic and lymphatic diseasesmedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overSalvage TherapyMyeloid Neoplasiabusiness.industryRemission InductionRetrospective cohort studyHematologyDNA MethylationMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaLeukemia Myeloid Acute030104 developmental biologymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAdolescent; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Cohort Studies; DNA Methylation; Databases Factual; Decitabine; Humans; Leukemia Myeloid Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adultbusinessmedicine.drug
researchProduct

The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in …

2016

The objective of this study was the elucidation of the possible role of the single-nucleotide polymorphisms (SNP) at position -29 and 2039 of the FSH receptor gene (FSHR) as independent predictive markers of ovarian response. Indeed, the tailoring of reproductive treatments is crucial for both maximizing the success of IVF patients and obtaining a reduction in hypo- or hyper-response rates. This prospective, observational study analyzed the association of -29 and 2039 FSHR polymorphisms with the number of retrieved oocytes in 140 patients attending an IVF/ICSI cycle for severe male factors (≤5,000,000 spermatozoa/mL) or tubal factors at the ANDROS Day Surgery Clinic, Palermo, Italy. The res…

0301 basic medicineAdultmedicine.medical_specialtyClinical variablesAdolescentGenotypePregnancy RateOocyte RetrievalFertilization in VitroBiology03 medical and health sciences0302 clinical medicineOvulation InductionPregnancyInternal medicineCOHmedicineGeneticsSNPHumansSperm Injections IntracytoplasmicAlleleGenetics (clinical)AllelesTreatment personalization030219 obstetrics & reproductive medicineIVF/ICSISurgery clinicObstetrics and GynecologyGeneral MedicineIvf icsiHuman genetics030104 developmental biologyEndocrinologyReproductive MedicineFSH receptor polymorphismOocytesReceptors FSHFemaleFsh receptor geneFollicle-stimulating hormone receptorDevelopmental Biology
researchProduct

Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.

2016

Background Non-classic congenital hyperplasia (NCAH) due to 21-hydroxylase deficiency is a common autosomal recessive disorder characterized by androgen excess. Objective and rationale We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of NCAH. A meta-analysis of epidemiological data was also performed. Search methods Peer-reviewed studies evaluating NCAH published up to October 2016 were reviewed. Multiple databases were searched including MEDLINE, EMBASE, Cochrane, ERIC, EBSCO, dissertation abstracts, and current contents. Outcomes The worldwide prevalence of NCAH amongst women presen…

0301 basic medicineAdultmedicine.medical_specialtyPediatricsHirsutismAdolescentGenetic counseling030209 endocrinology & metabolismDiseaseMiscarriage03 medical and health sciences0302 clinical medicinemedicineHumansCongenital adrenal hyperplasiahirsutismMenstruation DisturbancesGynecologyPregnancyAdrenal Hyperplasia Congenitalbusiness.industry17-alpha-HydroxyprogesteroneHyperandrogenismObstetrics and GynecologyAndrogen Antagonistsmedicine.diseasePolycystic ovary030104 developmental biologyReproductive MedicineFemalebusinessInfertility FemaleHuman reproduction update
researchProduct